

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)



(10) International Publication Number
WO 2023/161229 A1

(51) International Patent Classification:

A61P 3/10 (2006.01) C07K 14/575 (2006.01)

(21) International Application Number:

PCT/EP2023/054317

(22) International Filing Date:

21 February 2023 (21.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22158188.7 23 February 2022 (23.02.2022) EP

(71) Applicant: CORTERIA PHARMACEUTICALS

[FR/FR]; 128 rue la Boétie, 75008 Paris (FR).

(72) Inventors: JANIÁK, Philip; 128 Rue la Boétie, 75008

Paris (FR). OZOUX, Marie-Laure; 128 Rue La Boétie, 75008 Paris (FR). ROVERSI, Daniela; Via Pontina Km 30,600, 00071 Pomezia (IT). BIANCHI, Elisabetta; Via Pontina Km 30,600, 00071 Pomezia (IT). TRIPEPI, Martina; Via Pontina Km 30,600, 00071 Pomezia (IT). SANTOPRETE, Alessia; Via Pontina Km 30,600, 00071 Pomezia (IT).

(74) Agent: ARNOLD & SIEDSMA; Bezuidenhoutseweg 57,

2594 AC THE HAGUE (NL).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY

(57) Abstract: The present disclosure provides compounds which are peptides comprising the amino acid sequence of the formula (I) disclosed herein or pharmaceutically acceptable salts thereof. The compounds act as agonists of the corticotropin-releasing factor receptor 2 (CRF2) and are useful in therapy, especially in the treatment or prevention of cardiovascular diseases, kidney disease, obesity, diabetes, sarcopenia, particularly obesity-linked sarcopenia, heart failure, cachexia, and pulmonary hypertension.

WO 2023/161229 A1